These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 16076691)
21. Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions. Goldberg RM; Hurwitz HI; Fuchs CS Clin Adv Hematol Oncol; 2005 Dec; 3(12):1-10; quiz 11. PubMed ID: 16555433 [TBL] [Abstract][Full Text] [Related]
22. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Grothey A Oncology (Williston Park); 2006 Dec; 20(14 Suppl 10):21-8. PubMed ID: 17354514 [TBL] [Abstract][Full Text] [Related]
23. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Chase JL Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549 [TBL] [Abstract][Full Text] [Related]
26. Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer. Grothey A Semin Oncol; 2006 Oct; 33(5 Suppl 10):S41-9. PubMed ID: 17145524 [TBL] [Abstract][Full Text] [Related]
27. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Van Cutsem E Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643 [TBL] [Abstract][Full Text] [Related]
28. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Saif MW; Elfiky A; Salem RR Ann Surg Oncol; 2007 Jun; 14(6):1860-9. PubMed ID: 17356952 [TBL] [Abstract][Full Text] [Related]
29. [A perspective: role of targeted therapy in colon cancer]. Chung HH; Jang BI Korean J Gastroenterol; 2013 Mar; 61(3):128-35. PubMed ID: 23575231 [TBL] [Abstract][Full Text] [Related]
33. CALGB/SWOG C80405: A phase III trial of FOLFIRI or FOLFOX with bevacizumab or cetuximab or both for untreated metastatic adenocarcinoma of the colon or rectum. Clin Adv Hematol Oncol; 2006 Jun; 4(6):452-3. PubMed ID: 16981668 [No Abstract] [Full Text] [Related]
34. Targeted therapy in colorectal cancer: do we know enough? Pantaleo MA; Palassini E; Labianca R; Biasco G Dig Liver Dis; 2006 Feb; 38(2):71-7. PubMed ID: 16289975 [TBL] [Abstract][Full Text] [Related]
35. Targeted strategies in the treatment of metastatic colon cancer. Reidy D; Saltz L J Natl Compr Canc Netw; 2007 Oct; 5(9):983-90. PubMed ID: 17977504 [TBL] [Abstract][Full Text] [Related]
37. Biological therapy and other novel therapies in early-stage disease: are they appropriate? Grothey A Clin Cancer Res; 2007 Nov; 13(22 Pt 2):6909s-12s. PubMed ID: 18006799 [TBL] [Abstract][Full Text] [Related]
38. An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Hobday TJ Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S11-8. PubMed ID: 15871761 [TBL] [Abstract][Full Text] [Related]